NDRA Stock Overview
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ENDRA Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.26 |
| 52 Week High | US$2.79 |
| 52 Week Low | US$0.22 |
| Beta | 1.0 |
| 1 Month Change | -71.44% |
| 3 Month Change | -74.77% |
| 1 Year Change | -84.06% |
| 3 Year Change | -99.49% |
| 5 Year Change | -99.13% |
| Change since IPO | -99.67% |
Recent News & Updates
Recent updates
ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks
Sep 29ENDRA Life Sciences receives European patent for TAEUS system
Aug 24Endra Life Sciences Q2 2022 Earnings Preview
Aug 12We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Aug 08
We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Nov 18We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully
Jul 19ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer
Jun 15ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology
Jan 13ENDRA Life Sciences renews GE Healthcare collaboration agreement
Dec 21Endra Life prices $5M-share offering
Dec 16Endra Life Sciences EPS beats by $0.02
Nov 16Shareholder Returns
| NDRA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 12.6% | 1.8% | 1.2% |
| 1Y | -84.1% | -0.5% | 24.9% |
Price Volatility
| NDRA volatility | |
|---|---|
| NDRA Average Weekly Movement | 17.5% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NDRA's share price has been volatile over the past 3 months.
Volatility Over Time: NDRA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 21 | Francois Michelon | www.endrainc.com |
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person’s body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
ENDRA Life Sciences Inc. Fundamentals Summary
| NDRA fundamental statistics | |
|---|---|
| Market cap | US$2.81m |
| Earnings (TTM) | -US$10.06m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs NDRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NDRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.06m |
| Earnings | -US$10.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.1% |
How did NDRA perform over the long term?
See historical performance and comparison